NASDAQ$BBNX
Beta Bionics Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close
Briefing
Beta Bionics reported Q4 2025, revenue of $32.1M, net loss of $13.5M, diluted EPS of $-0.30.
For Q4 2025, Beta Bionics reported revenue of $32.1M, a net loss of $13.5M, diluted EPS was $-0.30. Management discusses segment performance, capital allocation, and outlook in the earnings release.
- Revenue $32.1M.
- Net loss $13.5M.
- Diluted EPS $-0.30.
Headline financials
Revenue & EPS history
Beta Bionics Inc · Revenue · Quarterly
$32.1M
Forward guidance
The release discusses Beta Bionics's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- Beta Bionics cites operational execution and demand trends supporting the outlook.
- Balance sheet and capital actions aim to fund growth and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q4 2025.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q4 2025
-0.7%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+18.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+4.8%
Q2 2025
Best reaction
-5.0%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -13.5% | -17.7% | |
| Q4 2025 | -2.6% | -1.5% | -23.4% | |
| Q3 2025 | +2.2% | +14.6% | +29.9% | |
| Q2 2025 | +4.8% | +17.2% | +33.7% | |
| Q1 2025 | -2.8% | +19.4% | +67.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro